

*Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**WEGO 威高**

山東威高集團醫用高分子製品股份有限公司

**Shandong Weigao Group Medical Polymer Company Limited**\*

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1066)**

## **PROPOSED AMENDMENT OF THE ARTICLES OF ASSOCIATION**

This announcement is made by Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

### **(1) THE PROPOSED AMENDMENT**

The Company proposes to amend Article 14 of its articles of association by the addition of the underlined and bold text as set out below (the “**Proposed Amendment**”).

\* *For identification purpose only*

**Article 14** Scope of operations: production and sale of medical polymer materials and products, plastic products (exclusive of agricultural film), sanitary raw and auxiliary materials, extracorporeal circulation and blood processing equipment, syringe and puncture devices, equipment and devices in the operation room, first-aid room and treatment room, clinical examination and analysis instruments, electronic devices, physiotherapy and rehabilitation equipment, medical cryotherapy, low temperature and refrigeration equipment and devices; production and sale of large-volume injection (including blood preservative solution), in vitro diagnostic reagents, medical test and basic equipment, implant materials and artificial organs, interventional equipment, medical suture materials and adhesives, **basic surgical instruments, dental surgical instruments, abdominal surgical instruments, urinary anorectal surgical instruments, medical optical instruments & apparatus and endoscopy devices, medical ultrasonic instruments and relevant devices, physiotherapy and rehabilitation equipment, medical X-ray equipment, ward nursing equipment and instruments, disinfection and sterilization equipment and instruments, medical cold therapy, cryogenic refrigeration equipment apparatus,** dental materials, production and sale of moulds, import and export of goods, import and export of technologies (excluding the distribution business of imported goods); medical supplies, pharmaceuticals, food, agricultural products, cosmetics, health products, such as irradiation sterilization, disinfection and treatment; irradiation technology consulting services; operation of special medical vehicle (blood collection, ambulance, physical examination) (Business projects that are subject to approval in accordance with law may only be carried out after the approval of the relevant departments, validity is subject to the permit granted.)

## **(2) REASONS FOR THE PROPOSED AMENDMENT**

The Proposed Amendment will allow the Company to diversify the range of products that it may offer.

### **(3) EXTRAORDINARY GENERAL MEETING**

The Proposed Amendment is subject to the approval by the shareholders of the Company by way of a special resolution and the approval, registration and filing with the relevant government authorities of the People's Republic of China.

The extraordinary general meeting (the "EGM") for the shareholders of the Company to approve the Proposed Amendment is scheduled to be held on Monday, 29 April 2019.

A circular containing further details of the Proposed Amendment, together with the relevant notice of the meeting and a proxy form, will be despatched to the shareholders of the Company on or about 13 March 2019.

### **(4) CLOSURE OF REGISTER OF MEMBERS**

For the purpose of determining the list of shareholders of the Company who are entitled to attend and vote at the EGM, the register of members of the Company will be closed from Thursday, 28 March 2019 to Monday, 29 April 2019 (both days inclusive). No transfer of Shares will be registered during this period.

In order to qualify for attending the EGM, shareholders of the Company should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H share registrar, Tricor Standard Limited at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong, for registration no later than 4:30p.m. on Wednesday, 27 March 2019.

By Order of the Board

**Shandong Weigao Group Medical Polymer Company Limited**

**Zhang Hua Wei**

*Chairman*

Hong Kong, 7 March 2019

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Long Jing (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mr. Wang Yi (*Non-executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)